Mechanistic understanding of the different effects of Wuzhi Tablet (Schisandra sphenanthera extract) on the absorption and first-pass intestinal and hepatic metabolism of Tacrolimus (FK506)

International Journal of Pharmaceutics

Volumn 389, Issue 1-2, 2010, Pages 114-121

  Qin, Xiao Ling ^a   Bi, Hui Chang ^a,b   Wang, Xue Ding ^a   Li, Jia Li ^a   Wang, Ying ^a   Xue, Xin Ping ^a   Chen, Xiao ^a   Wang, Chang Xi ^a   Xu, Le Jia ^a   Wang, Yi Tao ^b   Huang, Min ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF MACAU   (Macao)

Author keywords

CYP3A; First pass metabolism; P gp; Pharmacokinetics; Schisandra sphenanthera; Tacrolimus

Indexed keywords

GLYCOPROTEIN P; HERBACEOUS AGENT; SCHISANDRA SPHENANTHERA EXTRACT; TACROLIMUS; UNCLASSIFIED DRUG; VERAPAMIL; WUZHI;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; FIRST PASS EFFECT; IN VITRO STUDY; IN VIVO STUDY; LIVER METABOLISM; MALE; MICROSOME; NONHUMAN; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; TABLET;

EID: 77349105712     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.01.025     Document Type: Article

References (35)

1. Bi H.C., Zuo Z., Chen X., Xu C.S., Wen Y.Y., Sun H.Y., Zhao L.Z., Pan Y., Deng Y., Liu P.Q., Gu L.Q., Huang Z.Y., Zhou S.F., and Huang M. Preclinical factors affecting the pharmacokinetic behaviour of tanshinone IIA, an investigational new drug isolated from Salvia miltiorrhiza for the treatment of ischaemic heart diseases. Xenobiotica 38 (2008) 185-222
2. Bowman L.J., and Brennan D.C. The role of tacrolimus in renal transplantation. Expert Opin. Pharmacother. 9 (2008) 635-643
3. Davies B., and Morris T. Physiological parameters in laboratory animals and humans. Pharm. Res. 10 (1993) 1093-1095
4. Egashira K., Ohtani H., Itoh S., Koyabu N., Tsujimoto M., Murakami H., and Sawada Y. Inhibitory effects of pomelo on the metabolism of tacrolimus and the activities of CYP3A4 and P-glycoprotein. Drug Metab. Dispos. 32 (2004) 828-833
5. Fisher G.A., and Sikic B.I. Clinical studies with modulators of multidrug resistance. Hematol. Oncol. Clin. North Am. 9 (1995) 363-382
6. Fukatsu S., Fukudo M., Masuda S., Yano I., Katsura T., Ogura Y., Oike F., Takada Y., and Inui K.I. Delayed effect of grapefruit juice on pharmacokinetics and pharmacodynamics of tacrolimus in a living-donor liver transplant recipient. Drug Metab. Pharmacokinet. 63 (2006) 721-722
7. Herbert M.F., Park J.M., Chen Y.L., Akhtar S., and Larson A.M. Effects of St. John's Wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers. J. Clin. Pharmacol. 44 (2004) 89-94
8. Huyke C., Engel K., Simon-Haarhaus B., Quirin K.W., and Schempp C.M. Composition and biological activity of different extracts from Schisandra sphenanthera and Schisandra chinensis. Planta Med. 73 (2007) 1116-1126
9. Iwasaki K. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab. Pharmacokinet. 22 (2007) 328-335
10. Iwata H., Tezuka Y., Kadota S., Hiratsuka A., and Watabe T. Identification and characterization of potent CYP3A4 inhibitors in Schisandra fruit extract. Drug Metab. Dispos. 32 (2004) 1351-1358
11. Jeong H., and Chiou W.L. Role of P-glycoprotein in the hepatic metabolism of tacrolimus. Xenobiotica 36 (2006) 1-13
12. Jusko W.J., Thomson A.W., Fung J., McMaster P., Wong S.H., Zylber-Katz E., Christians U., Winkler M., Fitzsimmons W.E., and Lieberman R. Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther. Drug Monit. 17 (1995) 606-614
13. Lampen A., Christians U., Gonschior A.K., Bader A., Hackbarth I., von Engelhardt W., and Sewing K.F. Metabolism of the macrolide immunosuppressant, tacrolimus, by the pig gut mucosa in the Ussing chamber. Br. J. Pharmacol. 117 (1996) 1730-1734
14. Lemahieu W., and Maes B. In vivo assessment of cytochrome P450 3A4 and P-glycoprotein activity: impact on clinical practice. Curr. Enzyme Inhib. 3 (2007) 217-241
15. Li J.L., Wang X.D., Wang C.X., Fu Q., Liu L.S., Huang M., and Zhou S.F. Rapid and simultaneous determination of tacrolimus (FK506) and diltiazem in human whole blood by liquid chromatography-tandem mass spectrometry: application to a clinical drug-drug interaction study. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 867 (2008) 111-118
16. Loo W.T., Cheung M.N., and Chow L.W. Fructus schisandrae (Wuweizi)-containing compound inhibits secretion of HBsAg and HBeAg in hepatocellular carcinoma cell line. Biomed. Pharmacother. 61 (2007) 606-610
17. Mentzer Jr. R.M., Jahania M.S., Lasley R.D., and The U.S. Multicenter FK506 Study Group. Tacrolimus as a rescue immunosuppressant after heart and lung transplantation. Transplantation 65 (1998) 109-113
18. Pawarode A., Shukla S., Minderman H., Fricke S.M., Pinder E.M., O'Loughlin K.L., Ambudkar S.V., and Baer M.R. Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins. Cancer Chemother. Pharmacol. 60 (2007) 179-188
19. Pan Q.R., Wang T., Lu Q., and Hu X. Schisandrin B-a novel inhibitor of P-glycoprotein. Biochem. Biophys. Res. Commun. 335 (2005) 406-411
20. Peynaud D., Charpiat B., Vial T., Gallavardin M., and Ducerf C. Tacrolimus severe overdosage after intake of masked grapefruit orange marmalade. Eur. J. Clin. Pharmacol. 63 (2007) 721-722
21. Qin, X.L., Bi, H.C., Wang, C.X., Li, J.L., Wang, X.D., Liu, L.S., Chen, X., Huang, M., 2010. Study of the effect of Wuzhi tablet (Schisandra sphenanthera extract) on tacrolimus tissue distribution in rat by liquid chromatography tandem mass spectrometry method. Biomed. Chromatogr., doi:10.1002/bmc.1305.
22. Schmiedlin-Ren P., Thummel K.E., Fisher J.M., Paine M.F., Lown K.S., and Watkins P.B. Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3. Mol. Pharmacol. 51 (1997) 741-754
23. Staatz C.E., and Tett S.E. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin. Pharmacokinet. 43 (2004) 623-653
24. Sun M., Xu X., Lu Q., Pan Q., and Hu X. Schisandrin B: a dual inhibitor of P-glycoprotein and multidrug resistance-associated protein 1. Cancer Lett. 246 (2007) 300-307
25. Takada K., Usuda H., Oh-Hashi M., Yoshikawa H., Muranishi S., and Tanaka H. Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administrations to rats. J. Pharmacobiodyn. 14 (1991) 34-42
26. Tamura S., Ohike A., Ibuki R., Amidon G.L., and Yamashita S. Tacrolimus is a class II low-solubility high-permeability drug: the effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. J. Pharm. Sci. 91 (2002) 719-729
27. Undre N.A., Stevenson P., and Schafer A. Pharmacokinetics of tacrolimus: clinically relevant aspects. Transplant. Proc. 31 (1999) 21S-24S
28. van Gelder T. Drug interactions with tacrolimus. Drug Saf. 25 (2002) 707-712
29. Venkataramanan R., Swaminathan A., Prasad T., Jain A., Zuckerman S., Warty V., McMichael J., Lever J., Burckart G., and Starzl T. Clinical pharmacokinetics of tacrolimus. Clin. Pharmacokinet. 29 (1995) 404-430
30. Wilkinson G.R. Plasma and tissue binding considerations in drug disposition. Drug Metab. Rev. 14 (1983) 427-465
31. Wu C.Y., Benet L.Z., Hebert M.F., Gupta S.K., Rowland M., Gomez D.Y., and Wacher V.J. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin. Pharmacol. Ther. 58 (1995) 492-497
32. Xin H.W., Wu X.C., Li Q., Yu A.R., Zhu M., Shen Y., Su D., and Xiong L. Effects of Schisandra sphenanthera extract on the pharmacokinetics of tacrolimus in healthy volunteers. Br. J. Clin. Pharmacol. 64 (2007) 469-475
33. Yoo H.H., Lee M., Lee M.W., Lim S.Y., Shin J., and Kim D.H. Effects of Schisandra lignans on P-glycoprotein-mediated drug efflux in human intestinal Caco-2. Planta Med. 73 (2007) 444-450
34. Zhang J., Huang M., Guan S., Bi H.C., Pan Y., Duan W., Chan S.Y., Chen X., Hong Y.H., Bian J.S., Yang H.Y., and Zhou S. A mechanistic study of the intestinal absorption of cryptotanshinone, the major active constituent of Salvia miltiorrhiza. J. Pharmacol. Exp. Ther. 317 (2006) 1285-1294
35. Zhou S., Feng X., Kestell P., Paxton J.W., Baguley B.C., and Chan E. Transport of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide by human intestinal Caco-2 cells. Eur. J. Pharm. Sci. 24 (2005) 513-524